Type 1 Diabetes (T1D) Market Size and Forecast, By Insulin Analog (rapid Acting, long Acting, Premix Analogs), and Trend Analysis, 2014-2024

  • ID: 4429435
  • Report
  • 65 pages
  • Hexa Research
1 of 4

FEATURED COMPANIES

  • ADOCIA
  • Biocon
  • Bioton
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • MORE
The global type 1 diabetes market is expected to reach USD 25.52 billion by 2024. A significant increase in the prevalence of type 1 diabetes coupled with Rigorous research & development activities to introduce novel formulations drives the T1D market growth.

Sedentary lifestyles, unhealthy diet habits coupled with rising obesity rates will further enhance the uptake of various types of insulin for the treatment of this disorder. Though this type of diabetes is rare still the number of cases is increasing by 3% every year according to the data enumerated by the International Diabetes Federation (IDF).

Insulin therapy is very much essential in the patients who have type 1 diabetes. Rising launch of the novel insulin formulations along with several adjunct therapies will positively impact the insulin acceptance. On the other hand, this chronic disorder poses a significant economic impact owing to the increasing cost of insulin coupled with other conditions such as cardiac disorders, kidney disease among others. This affects the respective countries and their national healthcare systems. For instance, the expenditure on diabetes management accounts for around 5% to 20% of the total healthcare spending.

Rapid-acting, long-acting and premix analogs are the three major types of insulin analogs administered to the patients. These insulin types when delivered duplicate the action of natural insulin and avoid the excess release of glucose in blood cells. The market penetration of long-acting insulin products is higher as compared to other two types, however, during the forecast period, the uptake and acceptance of rapid and premix analogs are anticipated to increase. The reason being the quick action and optimum performance of these two over long-acting insulin.

The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total market share. The reason being extensive product offerings and continuous research and development activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies. Also, high probability of launch of several biosimilars by new entrants, major players might face competition during the forecast period.

To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are continuously investing in the development of the improved versions of insulin products. For instance, recent launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors exhibit the promising growth for type 1 diabetes treatment market.

PLEASE NOTE: This report will be dispatched approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ADOCIA
  • Biocon
  • Bioton
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • MORE
Chapter 1. Market Summary
1.1. Market trends & movement

Chapter 2. Global Type 1 Diabetes (T1D) Market Trends: Drivers & Opportunities
2.1. Introduction
2.2. Market drivers
2.3. Market restraints
2.4. Pipeline analysis
2.5. Novel insulin therapies
2.6. Porter's Five Forces analysis
2.7. SWOT

Chapter 3. Global Type 1 Diabetes (T1D) Market Trends, By Insulin Analog
3.1. Global Type 1 Diabetes (T1D) market movement, by Insulin Analog, 2016 & 2024
3.1.1. Rapid Acting Insulin
3.1.1.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.2. Long Acting Insulin
3.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
3.1.3. Premix Analogs
3.1.3.1. Market estimates and forecast, 2014-2024 (USD Million)

Chapter 4. Global Type 1 Diabetes (T1D) Market Trends, By Region
4.1. Global Type 1 Diabetes (T1D) market movement, by region, 2016 & 2024
4.1.1. North America
4.1.1.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.1.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
4.1.2. Europe
4.1.2.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.2.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
4.1.3. Asia Pacific
4.1.3.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.3.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
4.1.4. Rest of the World (RoW)
4.1.4.1. Market estimates and forecast, 2014-2024 (USD Million)
4.1.4.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)

Chapter 5. Key Country Markets
5.1. U.S.
5.1.1. Market estimates and forecast, 2014-2024 (USD Million)
5.1.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
5.2. U.K.
5.2.1. Market estimates and forecast, 2014-2024 (USD Million)
5.2.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
5.3. China
5.3.1. Market estimates and forecast, 2014-2024 (USD Million)
5.3.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)
5.4. India
5.4.1. Market estimates and forecast, 2014-2024 (USD Million)
5.4.2. Market estimates and forecast, by insulin analog, 2014-2024 (USD Million)

Chapter 6. Competitive Landscape
6.1. Competitive landscape analysis, 2016
6.2. Strategic framework
6.3. Potential customer base concentration
6.4. Company market positioning
6.5. Company profiles
6.5.1. ADOCIA
6.5.1.1. Company Overview
6.5.1.2. Product Benchmarking
6.5.1.3. Financial Performance
6.5.1.4. Recent Initiatives
6.5.2. Biocon
6.5.2.1. Company Overview
6.5.2.2. Product Benchmarking
6.5.2.3. Financial Performance
6.5.2.4. Recent Initiatives
6.5.3. Bioton
6.5.3.1. Company Overview
6.5.3.2. Product Benchmarking
6.5.3.3. Financial Performance
6.5.3.4. Recent Initiatives
6.5.4. Eli Lilly and Company
6.5.4.1. Company Overview
6.5.4.2. Product Benchmarking
6.5.4.3. Financial Performance
6.5.4.4. Recent Initiatives
6.5.5. Novo Nordisk
6.5.5.1. Company Overview
6.5.5.2. Product Benchmarking
6.5.5.3. Financial Performance
6.5.5.4. Recent Initiatives
6.5.6. Sanofi
6.5.6.1. Company Overview
6.5.6.2. Product Benchmarking
6.5.6.3. Financial Performance
6.5.6.4. Recent Initiatives
6.5.7. Wockhardt
6.5.7.1. Company Overview
6.5.7.2. Product Benchmarking
6.5.7.3. Financial Performance
6.5.7.4. Recent Initiatives
6.5.8. List of other vendors

Chapter 7. Methodology and Scope
7.1. Research methodology
7.2. Research Scope & Assumptions
7.3. List of data sources

*Full List of Tables & Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • ADOCIA
  • Biocon
  • Bioton
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Wockhardt
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll